Epithelial Ovarian Cancer: Disease and Pipeline Analysis - Product Thumbnail Image

Epithelial Ovarian Cancer: Disease and Pipeline Analysis

  • Report
  • 98 Pages
From
Ovarian Cancer - Pipeline Review, H2 2017 - Product Thumbnail Image

Ovarian Cancer - Pipeline Review, H2 2017

  • Report
  • 2232 Pages
From
Ovarian Cancer-Pipeline Insights, 2016 - Product Thumbnail Image

Ovarian Cancer-Pipeline Insights, 2016

  • Drug Pipelines
  • 260 Pages
From
Ovarian Cancer - Pipeline Review, H1 2017 - Product Thumbnail Image

Ovarian Cancer - Pipeline Review, H1 2017

  • Report
  • 2027 Pages
From
Epithelial Ovarian Cancer - Pipeline Review, H2 2016 - Product Thumbnail Image

Epithelial Ovarian Cancer - Pipeline Review, H2 2016

  • Report
  • 507 Pages
From
Epithelial Ovarian Cancer - Pipeline Review, H1 2016 - Product Thumbnail Image

Epithelial Ovarian Cancer - Pipeline Review, H1 2016

  • Report
  • 479 Pages
From
Epithelial Ovarian Cancer - Pipeline Review, H2 2015 - Product Thumbnail Image

Epithelial Ovarian Cancer - Pipeline Review, H2 2015

  • Report
  • 450 Pages
From
Metastatic Breast Cancer - Pipeline Review, H2 2016 - Product Thumbnail Image

Metastatic Breast Cancer - Pipeline Review, H2 2016

  • Report
  • 1096 Pages
From
Breast Cancer - Pipeline Review, H1 2016 - Product Thumbnail Image

Breast Cancer - Pipeline Review, H1 2016

  • Report
  • 3011 Pages
From
Metastatic Breast Cancer - Pipeline Review, H1 2016 - Product Thumbnail Image

Metastatic Breast Cancer - Pipeline Review, H1 2016

  • Report
  • 1079 Pages
From
Metastatic Breast Cancer - Pipeline Review, H2 2015 - Product Thumbnail Image

Metastatic Breast Cancer - Pipeline Review, H2 2015

  • Report
  • 966 Pages
From
Metastatic Breast Cancer - Pipeline Review, H1 2015 - Product Thumbnail Image

Metastatic Breast Cancer - Pipeline Review, H1 2015

  • Report
  • 866 Pages
From
HPAPIs and Cytotoxic Drugs Manufacturing Market (2nd Edition), 2016 - 2026 - Product Thumbnail Image

HPAPIs and Cytotoxic Drugs Manufacturing Market (2nd Edition), 2016 - 2026

  • Report
  • 345 Pages
From
Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) - Pipeline Review, H1 2018 - Product Thumbnail Image

Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) - Pipeline Review, H1 2018

  • Report
  • 74 Pages
From
Malignant Mesothelioma - Pipeline Review, H1 2018 - Product Thumbnail Image

Malignant Mesothelioma - Pipeline Review, H1 2018

  • Report
  • 612 Pages
From
Peritoneal Cancer - Pipeline Review, H1 2018 - Product Thumbnail Image

Peritoneal Cancer - Pipeline Review, H1 2018

  • Report
  • 1000 Pages
From
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review, H2 2017 - Product Thumbnail Image

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review, H2 2017

  • Report
  • 766 Pages
From
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review, H1 2017 - Product Thumbnail Image

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review, H1 2017

  • Report
  • 609 Pages
From
Ovarian Cancer Therapeutics in Asia-Pacific Markets to 2020 - Off-patent Chemo-regimens to Retain Dominance Despite New Launches - Product Thumbnail Image

Ovarian Cancer Therapeutics in Asia-Pacific Markets to 2020 - Off-patent Chemo-regimens to Retain Dominance Despite New Launches

  • Report
  • 126 Pages
From
Fallopian Tube Cancer - Pipeline Review, H1 2018 - Product Thumbnail Image

Fallopian Tube Cancer - Pipeline Review, H1 2018

  • Report
  • 950 Pages
From
Loading Indicator
adroll